2023 World Conference on Lung Cancer (Posters)-P2.12. Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan

P2.12. Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan - PDF(Abstract)

Back to course

Pdf Summary

This study, titled "Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan," aimed to investigate the use of biomarker testing and drug therapy in patients with non-small cell lung cancer (NSCLC) in Japan. The study was conducted retrospectively and partially prospectively, and enrolled 1,500 patients from 29 institutions.<br /><br />The results showed that multi-gene testing, including the Oncomine Dx Target Test (ODxTT) and other testing platforms, was performed in 48% of the patients. Of those who were tested, 67% had ODxTT. The positive rates for driver alterations such as EGFR, ALK, ROS1, BRAF, and MET were determined for adenocarcinomas and non-adenocarcinomas.<br /><br />Concordance rates between multi-gene testing and single-gene testing were examined for various driver alterations. The study found that the concordance rate tended to be poor for some genes. Notably, all patients who tested negative for multi-gene testing and positive for single-gene testing for ROS1 and MET did not receive targeted therapy at the clinician's discretion.<br /><br />The median overall survival for patients with Driver/Target therapy, Driver/Target therapy-, and Driver- was 24.3, 9.6, and 11.7 months, respectively. The study concluded that the prognosis for Driver patients without targeted therapy was not different from that of Driver- patients, but could be improved with appropriately performed biomarker testing and the initiation of targeted therapies.<br /><br />In summary, this study provides real-world data on biomarker testing, treatment strategy, and survival outcomes in patients with advanced or recurrent NSCLC in Japan. The study highlights the importance of biomarker testing in selecting adequate treatment and emphasizes the need for improved concordance rates between multi-gene testing and single-gene testing for certain genes. The findings suggest that targeted therapies can improve the prognosis for NSCLC patients when appropriately utilized.

Asset Subtitle

Takaaki Tokito

Meta Tag

Speaker Takaaki Tokito

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

Biomarker Diagnostics

Treatment Strategy

Survival Outcome

NSCLC

Japan

Biomarker Testing

Concordance Rates

Targeted Therapy

Overall Survival

Multi-Gene Testing